Nastech Receives Notice of Allowance for U.S. Patent Related to Methods for Identifying Cell-Specific Targeting Peptides
08 Janvier 2008 - 1:30PM
PR Newswire (US)
BOTHELL, Wash., Jan. 8 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. (NASDAQ:NSTK) announced today that the
U.S. Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for U.S. patent application No. 10/976,942, entitled
"Phage Displayed Trp Cage Ligands." The patent application has
claims that relate to a novel, high-throughput method for
identifying peptides which can bind to specific cell types. "A
major obstacle in the development of safe and effective medicines
today is the inability to target the therapeutic directly to the
cells of interest," stated Steven C. Quay, M.D., Ph.D., Chairman
and CEO of Nastech. "The technology of this allowed patent provides
Nastech with a process for rapidly identifying peptides that target
specific cells. These targeting peptides can then be combined with
therapeutics to enhance overall delivery and overcome this key
challenge in drug development." Nastech published in the March,
2007 issue of the Journal of Biological Chemistry results that
demonstrate the use of a proprietary phage display library to
screen protein to protein interactions and protein-DNA
interactions. Using this library Nastech can select peptides that
are able to target specific cell types. These peptides can then be
used to enhance the targeted delivery of therapeutic molecules and
diagnostic agents. About Nastech Nastech is a biopharmaceutical
company developing innovative products based on proprietary
molecular biology-based drug delivery technologies. Nastech is
creating technologies that enable the delivery of peptide and
protein therapeutics without the requirement of an injection, which
is currently the most common form of administration for this class
of drugs. Nastech has also established a wholly-owned subsidiary,
MDRNA, Inc., to focus on developing RNA-based technologies and
therapeutics. MDRNA is harnessing the power of RNA interference, a
cellular mechanism that can turn off the production of a specific
protein through use of small interfering RNAs (siRNAs), to develop
a new class of therapeutics by identifying key protein targets,
designing the siRNAs that will turn off the production of the
targeted proteins, and creating a formulation for the delivery of
the therapeutics. Nastech and its collaboration partners are
developing products for multiple therapeutic areas including
osteoporosis, obesity, diabetes, autism, respiratory diseases and
inflammatory conditions. For additional information about Nastech
please visit http://www.nastech.com/. Nastech Forward Looking
Statements Statements made in this press release may be
forward-looking statements within the meaning of Federal Securities
laws that are subject to certain risks and uncertainties and
involve factors that may cause actual results to differ materially
from those projected or suggested. Factors that could cause actual
results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of
Nastech or a subsidiary to obtain additional funding; (ii) the
ability of Nastech or a subsidiary to attract and/or maintain
manufacturing, research, development and commercialization
partners; (iii) the ability of Nastech, a subsidiary and/or a
partner to successfully complete product research and development,
including preclinical and clinical studies and commercialization;
(iv) the ability of Nastech, a subsidiary and/or a partner to
obtain required governmental approvals; and (v) the ability of
Nastech, a subsidiary and/or a partner to develop and commercialize
products that can compete favorably with those of competitors.
Additional factors that could cause actual results to differ
materially from those projected or suggested in any forward-looking
statements are contained in Nastech's most recent periodic reports
on Form 10-K and Form 10-Q that are filed with the Securities and
Exchange Commission. Nastech assumes no obligation to update and
supplement forward-looking statements because of subsequent events.
Contacts: Nastech Ed Bell Director, Investor Relations (425)
908-3639 Russo Partners, LLC David Schull (Media) (212) 845-4271
DATASOURCE: Nastech Pharmaceutical Company Inc. CONTACT: Ed Bell,
Director, Investor Relations of Nastech, +1-425-908-3639, ; or
David Schull, Media, of Russo Partners, LLC for Nastech,
+1-212-845-4271 Web site: http://www.nastech.com/
Copyright
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Nastech Pharmaceutical Company (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Nastech Pharmaceutical Company (MM)